Pfizer Slapped With Additional Patent Infringement Lawsuit Over Its Famed COVID-19 Shots

  • Arbutus Biopharma Corporation (NASDAQ: ABUS) and its licensee Genevant Sciences have sued Pfizer Inc (NYSE: PFE) and its partner BioNTech SE (NASDAQ: BNTX) in the U.S. District Court for the District of New Jersey, seeking damages for infringement of five U.S. patents.

  • Arbutus and Genevant Sciences seek compensation for the unlicensed use of patented lipid nanoparticle (LNP) delivery technologies in Pfizer/BioNTech’s famed COVID-19 vaccine.

  • The lawsuit by Arbutus and Genevant says Pfizer/BioNTech engaged in licensing discussions for the technology, but they did not “result in a settlement.”

  • Arbutus Biopharma sued Moderna Inc (NASDAQ: MRNA) in the Delaware court for infringing six patents in manufacturing and selling MRNA-1273, Moderna’s vaccine for COVID-19.

  • In their lawsuit against Moderna, Arbutus said they were not looking to block the company from selling, manufacturing, or distributing MRNA-1273 but seek fair compensation.

  • Moderna sued Pfizer and BioNTech for patent infringement filed between 2010 and 2016 covering foundational mRNA technology.

  • Last year in March, Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) filed separate lawsuits in the Delaware federal court against Pfizer and Moderna, seeking damages for infringement of a patent in the manufacture and sale of their mRNA COVID-19 vaccines.

  • Price Action: ABUS shares are down 1.80% at $3.01 on the last check Tuesday.

Don’t miss real-time alerts on your stocks – join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article Pfizer Slapped With Additional Patent Infringement Lawsuit Over Its Famed COVID-19 Shots originally appeared on


© 2023 Benzinga does not provide investment advice. All rights reserved.